Unichem Laboratories receives USFDA approval for Montelukast

Unichem Laboratories has received final USFDA approval for its Montelukast chewable tablets used for prevention and treatment of asthma. The product is a generic version of MerckSharp & Dohme Corporation’s Singulair tablets in the same strengths. The drug will be manufactured at its Goa facility. The tablets are indicated for prophylaxis and chronic treatment of asthma in adults and pediatric patients – 12 months of age and older They are also used in treatment of seasonal allergic rhinitis in adults and patients – 2 years of age and older, and perennial allergic rhinitis in patients – 6 months of age and older.

Company Profile : Unichem Laboratories Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.